Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | PTPRC | P08575 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 1/20 | 1.00 |
| ▸ | PTPRJ | Q12913 | 1/20 | 1.00 |
| ▸ | DUSP26 | Q9BV47 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738903 | 1.00 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL14154415 | 1.00 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL30542884 | 1.00 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL29391398 | 1.00 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL2401972 | 1.00 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL2401966 | 0.99 | PTPN11 (0.98) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL18874952 | 0.88 | PTPN11 (0.79) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL391667 | 0.86 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL31186847 | 0.86 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC | |
| SCHEMBL2401970 | 0.86 | PTPN11 (1.00) | PTPN11HSD17B10PTPN7ALOX15PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333698-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | UNIV GEORGIA STATE RES FOUND (US) | 2025-10-30 | — | — | US | claimed |
| US-20230220342-A1 | SIRPa Deficient Macrophages for Treating Cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | claimed |
| WO-2012154567-A2 | HUMAN INVASION SIGNATURE FOR PROGNOSIS OF METASTATIC RISK | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2012-11-15 | — | — | WO | claimed |
| US-20250333698-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | UNIV GEORGIA STATE RES FOUND (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250262194-A1 | PHARMACEUTICAL FOR TREATING OR PREVENTING CANCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-21 | — | — | US | disclosed |
| US-20250134885-A1 | USE OF SHP2 INHIBITORS FOR INHIBITING SENESCENCE | Université Toulouse III - Paul Sabatier (FR) | 2025-05-01 | — | — | US | disclosed |
| US-20250090529-A1 | USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-03-20 | — | — | US | disclosed |
| US-12240892-B2 | Pharmaceutical composition comprising expression or activity inhibitor of c-src for preventing or treating synucleinopathy | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-03-04 | — | — | US | disclosed |
| EP-4512401-A1 | PHARMACEUTICAL FOR TREATING OR PREVENTING CANCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-26 | — | — | EP | disclosed |
| EP-4423251-A1 | SIRP ALPHA DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023204259-A1 | PHARMACEUTICAL FOR TREATING OR PREVENTING CANCER | 中外製薬株式会社 | 2023-10-26 | — | — | WO | disclosed |
| US-20160129021-A1 | STERILIZATION METHOD | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-05-12 | — | — | US | disclosed |
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | RHODE ISLAND HOSPITAL (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | RHODE ISLAND HOSPITAL (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2014179095-A1 | STERILIZATION METHOD | UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140314786-A1 | HUMAN INVASION SIGNATURE FOR PROGNOSIS OF METASTATIC RISK | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2012154567-A2 | HUMAN INVASION SIGNATURE FOR PROGNOSIS OF METASTATIC RISK | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134885-A1 | USE OF SHP2 INHIBITORS FOR INHIBITING SENESCENCE | PPM1A, PPM1B, PPM1G | PTPN11 21/4885HSD17B10 2375/4885PTPN7 22/4885 |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | PTPN11 16/4885HSD17B10 2415/4885PTPN7 1/4885 |
| US-20160129021-A1 | STERILIZATION METHOD | PTPN1, PTPN5, PTPN2 | PTPN11 17/4885HSD17B10 2525/4885PTPN7 6/4885 |
| US-20250090529-A1 | USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE | PTPN1, PTPN7, PTPN21 | PTPN11 15/4885HSD17B10 2089/4885PTPN7 2/4885 |
| US-20250262194-A1 | PHARMACEUTICAL FOR TREATING OR PREVENTING CANCER | KRAS, NRAS, TP53 | PTPN11 27/4885HSD17B10 3296/4885PTPN7 37/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | PTPN11 3792/4885HSD17B10 2065/4885PTPN7 3199/4885 |
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | SOST, PTPN6, PTPN3 | PTPN11 7/4885HSD17B10 3850/4885PTPN7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.